Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Cisplatin
Drug ID BADD_D00474
Description Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
Indications and Usage For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
Marketing Status Prescription; Discontinued
ATC Code L01XA01
DrugBank ID DB00515
KEGG ID D00275
MeSH ID D002945
PubChem ID 5702198
TTD Drug ID D0U5HU
NDC Product Code 68001-283; 16729-288; 70860-206; 49452-2078; 72969-014; 63323-103; 68554-0077; 44567-510; 0703-5748; 49812-0009; 0703-5747; 54875-0001; 0143-9504; 44567-511; 50711-0001; 44567-530; 43744-068; 72659-864; 44567-509; 0143-9505; 68083-163; 68083-162
Synonyms Cisplatin | cis-Diamminedichloroplatinum(II) | Platinum Diamminodichloride | Diamminodichloride, Platinum | cis-Platinum | cis Platinum | Dichlorodiammineplatinum | cis-Diamminedichloroplatinum | cis Diamminedichloroplatinum | cis-Dichlorodiammineplatinum(II) | NSC-119875 | Platino | Platinol | Biocisplatinum | Platidiam
Chemical Information
Molecular Formula PtCl2(NH3)2
CAS Registry Number 15663-27-1
SMILES N.N.Cl[Pt]Cl
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.0020.013853%
Abdominal pain lower07.01.05.010--Not Available
Abdominal pain upper07.01.05.003--
Abdominal tenderness07.01.05.0040.001332%Not Available
Abscess11.01.08.0010.001865%Not Available
Activated partial thromboplastin time prolonged13.01.02.0010.000533%
Acute hepatic failure09.01.03.0010.000556%Not Available
Acute leukaemia01.10.02.001; 16.01.02.001--Not Available
Acute myeloid leukaemia01.10.05.001; 16.01.05.0010.000903%Not Available
Acute myocardial infarction02.02.02.001; 24.04.04.0010.001865%Not Available
Acute promyelocytic leukaemia01.10.05.003; 16.01.05.0030.000139%Not Available
Acute respiratory distress syndrome22.01.03.0010.000417%
Acute respiratory failure14.01.04.004; 22.02.06.0010.000486%Not Available
Ageusia07.14.03.003; 17.02.07.001--Not Available
Agitation17.02.05.012; 19.06.02.001--
Agranulocytosis01.02.03.0010.003463%Not Available
Alanine aminotransferase increased13.03.01.0030.003996%
Alopecia23.02.02.001--
Altered state of consciousness17.02.04.001; 19.07.01.0030.001865%Not Available
Amnesia17.03.02.001; 19.20.01.001--
Amylase increased13.05.01.009--
Anaemia01.03.02.0010.031969%
Anaphylactic reaction10.01.07.001; 24.06.03.0060.002131%
Anaphylactic shock10.01.07.002; 24.06.02.0040.001865%Not Available
Angioedema10.01.05.009; 23.04.01.001--Not Available
Anuria20.01.03.0020.000799%Not Available
Anxiety19.06.02.002--
Aortic aneurysm24.02.03.0010.000533%Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 26 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene